Navigation Links
PharmAthene Progresses Second Generation rPA Anthrax Vaccine
Date:10/31/2011

ANNAPOLIS, Md., Oct. 31, 2011 /PRNewswire/ -- PharmAthene, Inc. (NYSE Amex: PIP) announced today further development progress of its second generation rPA anthrax vaccine, SparVax™.  The new vaccine is being developed to provide rapid manufacturing scale-up to respond to a national security emergency.  The Company completed its first cGMP manufacturing run at 1,500 liter commercial scale.  Final analytical testing is ongoing and expected to be completed in December.

"There is widespread acknowledgement of the need for a modern, next-generation anthrax vaccine that can meet the government's needs in the event of an emergency.  A recombinant anthrax vaccine offers the potential for an improved vaccine that is safe, convenient, cost-effective and provides for a significant increase in production yields," remarked Eric I. Richman, President and Chief Executive Officer. "SparVax™ is the first medical countermeasure to successfully transition from early research funded by the National Institutes of Health (NIH) to advanced development in partnership with the Biomedical Advanced Research and Development Authority (BARDA).  SparVax™ represents how our medical countermeasure development program can create products with desired characteristics to meet the needs of our country.  We look forward to continuing a very productive collaboration with our partners in government to address this need and advance this important product."

"This achievement marks the latest in a series of accomplishments for our rPA anthrax vaccine program in 2011," commented Dr. Thomas Fuerst, Executive Vice President and Chief Scientific Officer. "Earlier this year, we successfully completed the technology transfer of our manufacturing process from the United Kingdom to a United States-based contract manufacturing organization.  Most importantly, PharmAth
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. PharmAthene Appoints Brian A. Markison to the Companys Board of Directors
2. PharmAthene Achieves Significant Progress in SparVax™ Anthrax Vaccine Program
3. Department of Defense Awards $5.7 Million Contract to PharmAthene for Nerve Agent Medical Countermeasure Program
4. PharmAthene Selected for Inclusion in the Russell Global Index and Russell 3000 Index
5. PharmAthene Achieves Anthrax Vaccine Program Milestone and Successfully Completes Technology Transfer
6. PharmAthene Completes $6.5 Million Registered Direct Offering
7. PharmAthene Reports First Quarter 2011 Financial and Operating Results
8. PharmAthene to Host Year-End 2010 Earnings Conference Call and Webcast on Monday, March 28, 2011
9. PharmAthene Strengthens Scientific Leadership and Program Management for Future Growth
10. PharmAthene Receives FDA Clearance to Reinitiate Clinical Testing of Valortim®
11. PharmAthene Reports Third Quarter 2010 Financial and Operational Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 23, 2014 PharmaBoardroom,s new ... today and available for free download , digs deep ... and growth in the sector today. One area ... has been in developing a homegrown pharmaceutical manufacturing base, even ... still remains some way off. A cursory comparison with neighboring ...
(Date:12/22/2014)... , Dec. 22, 2014   ... a developer of pathogen-specific therapies for serious ... protecting the microbiome, today announced positive topline ... 1a clinical trial of SYN-004, the Company,s ... of Clostridium difficile (C. difficile) ...
(Date:12/22/2014)... The American Journal of Hematology/Oncology, ... and editorials addressing developments and pathways related to ... provocative article exploring the role of follicle-stimulating hormone ... of prostate cancer. , The article references ... that there could be a connection to prostate ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one of the nation’s ... Pharm.D. to the newly created position of Vice President ... Dr. Maroulis will continue to manage the entire specialty ... pharmacies as the company expands. Dr. Maroulis has been ... has served in many different capacities in the pharmacy, ...
Breaking Biology Technology:PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2
... Trial conducted by Novartis evaluating safety and efficacy of Albuferon ... with genotypes 2 and 3 hepatitis C - , ... (Nasdaq: HGSI ) today announced that Novartis has ... trial to evaluate the safety and efficacy of Albuferon(R) (albinterferon ...
... , QUEBEC, June 18 /PRNewswire-FirstCall/ - Following the announcement ... partnership agreement between Victhom Human Bionics Inc. ("Victhom", TSX: ... announced today the completion of the transaction contemplated by ... and debenture holders of the concurrent restructuring of its ...
... NATICK, Mass., June 18 Boston Scientific Corporation (NYSE: ... 19th Annual Mid-Year Equity Conference, June 23 - 24. , ... make a 25-minute presentation on Wednesday, June 24th beginning at ... Executive Vice President and Chief Financial Officer will join Mr. ...
Cached Biology Technology:Human Genome Sciences Announces Completion of Enrollment in Phase 2b Monthly-Dosing Trial of Albuferon(R) 2Human Genome Sciences Announces Completion of Enrollment in Phase 2b Monthly-Dosing Trial of Albuferon(R) 3Human Genome Sciences Announces Completion of Enrollment in Phase 2b Monthly-Dosing Trial of Albuferon(R) 4Victhom announces completion of joint venture agreement with Otto Bock for Neurobionix activities 2Victhom announces completion of joint venture agreement with Otto Bock for Neurobionix activities 3Victhom announces completion of joint venture agreement with Otto Bock for Neurobionix activities 4
(Date:12/10/2014)... CIE San Diego has launched an innovative ... tissue that enhances care coordination among social service and ... information; earned a second $1 million grant from the ... aging in community and; will be recognized as a ... 4-6p. CIE San Diego today announced ...
(Date:12/10/2014)... California , December 9, 2014 ... with ITN,s BCARD Platform   ... cloud-based enterprise meeting scheduling solutions for business-to-business (B2B) ... the world leader in mobile near-field communication (NFC), ...      (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , ...
(Date:12/5/2014)... , Dec. 4, 2014  Tute Genomics, a leader ... million in Series A1 funding led by UK-based Eurovestech. ... participated in the investment round. "We are ... community adopts next-generation sequencing and seeks new approaches for ... Reid Robison , MD MBA, and CEO of Tute ...
Breaking Biology News(10 mins):Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
... scientists led by the New York-based Wildlife Conservation Society ... high-tech GPS (Global Positioning System) collars on eight saiga ... Asia's most bizarre-looking ?and endangered ?large mammals. , Standing ... about 50 pounds, the most striking feature of the ...
... ocean to rescue a dying coral reef from destruction in ... comic-book superhero Batman, a batfish has saved a coral reef ... fish was never previously known as a weed-eater. ... Reef Studies (CoECRS) who were studying how coral reefs are ...
... A fossil fish discovered in the West Australian Kimberley ... evolution, rewriting a century-old theory on how the first ... Erich Fitzgerald and Mr Tim Holland were part of ... Science Dr John Long, that made the spectacular discovery ...
Cached Biology News:Asia's odd-ball antelope gets collared 2Batfish to the rescue! 2
... Whether your projects are focused on sequencing, ... or in other areas of genomics and ... help you meet your research and manufacturing ... to take your project from beginning to ...
... Research Scale (gram quantities of IgY) , ... Prepare your Antigen), we segregate the appropriate number ... After 3 such eggs are collected (usually over ... injection series. This involves a total of four ...
... SOS Protein Solubility Service, We deliversoluble ... New SOS technology yields the best soluble ... applied on each clone submitted , Powerful ... ,The new protein Solubility Optimization Service (SOS) ...
... Panels were designed for full-length gene cloning ... to identify the desired cDNA clone. The ... 96-well "Master Plate," where each well contains ... the positive well(s) by gel electrophoresis of ...
Biology Products: